TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is anticipated to issue its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $13.20 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

TriSalus Life Sciences Trading Down 5.9%

Shares of NASDAQ:TLSI opened at $5.06 on Friday. The firm has a market cap of $252.80 million, a PE ratio of -2.50 and a beta of 0.42. The company has a fifty day simple moving average of $5.59 and a 200 day simple moving average of $5.33. TriSalus Life Sciences has a 12-month low of $3.42 and a 12-month high of $7.95.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. acquired a new position in TriSalus Life Sciences in the fourth quarter valued at approximately $72,000. Man Group plc bought a new stake in shares of TriSalus Life Sciences in the 4th quarter worth approximately $102,000. Abel Hall LLC acquired a new position in TriSalus Life Sciences during the 4th quarter valued at approximately $73,000. Kotler Kevin bought a new position in TriSalus Life Sciences during the 4th quarter worth $1,013,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in TriSalus Life Sciences in the fourth quarter worth $104,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Canaccord Genuity Group increased their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.00.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.